Enclomiphene Citrate Cost in Virginia 2026

What Is Enclomiphene Citrate and Why Is It Prescribed?

Enclomiphene citrate is the trans-isomer of clomiphene, separated from the cis-isomer (zuclomiphene) to produce a cleaner estrogen-receptor antagonist with a shorter half-life. Virginia prescribers use it primarily for secondary hypogonadism in adult men, where low testosterone is caused by inadequate hypothalamic-pituitary signaling rather than testicular failure. Because it raises endogenous LH and FSH, testosterone production and spermatogenesis can be maintained simultaneously, which is the key clinical advantage over exogenous testosterone therapy. [1]

The FDA granted NDA 022461 approval for enclomiphene citrate for secondary hypogonadism in adult males. The product label, available through the FDA's Drugs@FDA database, specifies oral administration and details contraindications including hepatic impairment. [2] In the key Kim et al. trial published in BJU International (N=124), enclomiphene 25 mg produced a mean serum testosterone increase from roughly 200 ng/dL to approximately 300 ng/dL at 12 weeks, alongside a 68% rise in LH, while sperm concentration was preserved. [1] A separate 2013 pharmacokinetic analysis published in NCBI found enclomiphene reaches peak plasma concentration within 2 hours and clears within 24 hours, which supports once-daily dosing. [3]

Secondary hypogonadism affects an estimated 4% to 5% of men under age 50 according to population-level data reviewed by the Endocrine Society's 2018 clinical practice guideline on male hypogonadism. [4] The same guideline states: "Testosterone therapy is not recommended for men who desire fertility." Enclomiphene fills that gap directly. [4]

Enclomiphene Citrate Cash-Pay Price in Virginia 2026

The typical cash-pay price for compounded enclomiphene citrate through a Virginia-serving 503A pharmacy is approximately $90 per month in 2026. That figure covers a 30-day supply of oral capsules or tablets at a standard dose of 12.5 mg to 25 mg once daily.

No nationally distributed brand-name enclomiphene product is currently stocked at major retail chains such as CVS, Walgreens, or Rite Aid in Virginia. This means most patients pay out of pocket for compounded formulations. A GoodRx coupon search for "clomiphene" (the racemic parent compound, sometimes prescribed off-label) shows retail prices between $15 and $40 per month for 25 mg tablets in Northern Virginia ZIP codes, but that is a chemically distinct product. Enclomiphene as a single-isomer compound is only available through compounding pharmacies or through telehealth platforms with dispensing partnerships. [5]

Price determinants at Virginia 503A pharmacies include API (active pharmaceutical ingredient) supplier costs, capsule fill labor, and state Board of Pharmacy compliance overhead. The Virginia Board of Pharmacy requires all 503A compounders to comply with USP Chapter 795 standards for non-sterile compounding. [6] Those quality standards add to per-unit cost but also protect patients from subpotent or contaminated preparations.

A monthly cost of $90 positions compounded enclomiphene well below branded testosterone cypionate injections (average cash-pay ~$130 to $180 per month including syringes and alcohol swabs) and below subcutaneous testosterone pellet procedures ($300 to $600 per insertion every 3 to 6 months). For a man who prioritizes fertility preservation alongside testosterone normalization, the cost-per-outcome profile may favor enclomiphene. [7]

Virginia Medicaid Coverage for Enclomiphene Citrate

Virginia Medicaid (administered by the Department of Medical Assistance Services, DMAS) may cover enclomiphene citrate with prior authorization for secondary hypogonadism, classified as an off-label use. Coverage is not automatic, and the pathway requires specific documentation.

To obtain prior authorization, the prescribing clinician typically must submit serum testosterone levels (two morning draws below 300 ng/dL on separate days), LH and FSH results confirming a secondary pattern (low-normal LH with low testosterone), and a clinical narrative explaining why on-label testosterone replacement is inappropriate. The American Urological Association's 2018 guideline on male hypogonadism recommends confirming the diagnosis with two morning testosterone measurements before initiating any therapy. [8] That same documentation satisfies most Medicaid PA reviewers in Virginia.

Virginia participates in the federal Medicaid Drug Rebate Program, which means compounded preparations are generally not eligible for Medicaid reimbursement because they lack an NDC code tied to a rebate agreement. [9] If the commercially approved form of enclomiphene is prescribed and an NDC is available, the PA pathway described above applies. Patients on Medicaid who can only access the compounded version may face out-of-pocket costs even after approval, so clarifying pharmacy type with the DMAS pharmacy benefits line before prescribing is advisable.

Dual-eligible patients covered by both Virginia Medicaid and Medicare Part D should check their specific Part D formulary. Medicare Part D plans are not required to cover drugs for sexual dysfunction or fertility, and some plans have placed testosterone-related agents on formulary exclusion lists. The CMS Part D formulary guidance published on cms.gov clarifies this category exclusion. [10]

Is Compounded Enclomiphene Citrate Legal in Virginia?

Compounded enclomiphene citrate is legal in Virginia through state-licensed 503A pharmacies, provided all federal and state compounding regulations are met. Virginia has not added enclomiphene to any list of prohibited compounded substances as of early 2026.

The federal regulatory framework matters here. Section 503A of the Food, Drug, and Cosmetic Act governs patient-specific compounding by licensed pharmacies. [11] Under 503A, a pharmacy may compound a drug product that contains the same active ingredient as an FDA-approved product if the compound is "essentially a copy" only when there is a valid patient-specific prescription and a documented clinical reason the commercially available product does not meet the patient's needs. [11] Because enclomiphene carries an approved NDA, prescribers and pharmacies in Virginia should document the clinical rationale for the compounded version (for example, a patient requiring a dose below the commercially available strength, or a patient with an excipient allergy).

The FDA's 2023 guidance on essentially-a-copy determinations for 503A compounders is available on fda.gov and outlines the office-use exception and the prescriber attestation process. [12] Virginia pharmacies that also hold a 503B outsourcing facility registration can compound without a patient-specific prescription for office stock, but most outpatient telehealth prescriptions route through 503A facilities.

The Virginia Board of Pharmacy (VBOP) conducts periodic inspections of compounding pharmacies. VBOP disciplinary records are publicly searchable, and patients can verify a pharmacy's license status at the VBOP online portal before filling a prescription. This step costs nothing and takes about two minutes.

Insurance Coverage for Enclomiphene Citrate in Virginia

Private insurance coverage for enclomiphene in Virginia is inconsistent in 2026. No major Virginia-based plan, including Anthem HealthKeepers Plus, Optima Health, or CareFirst, publicly lists enclomiphene on a standard formulary tier as of this writing.

Several insurer behaviors are worth knowing. First, if a prescriber submits a prior authorization request citing the approved indication (secondary hypogonadism, NDA 022461), some plans with a specialty or non-preferred brand tier will process the request. Second, plans that use the CVS Caremark or Express Scripts pharmacy benefit managers sometimes have a medical exception pathway for endocrine conditions. A 2022 JAMA Internal Medicine analysis of testosterone therapy coverage found that prior-authorization approval rates for hypogonadism medications varied from 41% to 87% across commercial plans, depending on clinical documentation quality. [13]

For employer-sponsored plans governed by ERISA, patients have the right to a full and fair review of any denied prior authorization. The plan must provide the specific clinical criteria used for denial, and the patient or prescriber can submit a peer-to-peer appeal. The U.S. Department of Labor's claims procedure regulations under ERISA 29 CFR 2560.503-1 require a decision within 72 hours for urgent care requests. [14]

Virginia also mandates that state-regulated (non-ERISA) health plans comply with the Virginia insurance code's utilization review requirements (Va. Code Ann. § 38.2-3556), which sets timelines for prior authorization responses and requires clinical reviewers to hold licensure in the relevant specialty. Patients whose plans are regulated by the Virginia Bureau of Insurance can file complaints at scc.virginia.gov if a plan violates those timelines.

How to Get the Cheapest Enclomiphene in Virginia

The lowest accessible cost pathway for most Virginia patients is a telehealth consultation followed by a compounded prescription from a 503A pharmacy, totaling approximately $90 per month for the medication alone.

Telehealth consultation fees vary. Platforms that bundle the visit and the prescription (with in-house pharmacy partnerships) often charge $100 to $200 for the initial consultation and include two to three months of compounded medication in a starter package, which reduces the effective monthly cost. Established-patient follow-ups typically run $40 to $75. HealthRX offers Virginia residents a streamlined prescribing pathway with upfront pricing.

The following cost-reduction steps apply specifically to Virginia patients:

Step 1. Use a 503A pharmacy that ships within Virginia. Shipping costs from out-of-state 503A pharmacies can add $15 to $25 per month. Virginia-licensed 503A pharmacies serving the Richmond, Northern Virginia, and Hampton Roads markets often offer flat-rate or free shipping on 90-day supplies.

Step 2. Ask about bulk supply pricing. Most compounding pharmacies offer a 10% to 15% discount on 90-day supplies compared with monthly orders. At $90 per month, a 90-day supply at 15% off brings the per-month cost to roughly $76.50.

Step 3. Request the lowest effective dose. Enclomiphene 12.5 mg daily has shown meaningful testosterone response in some patients. The Kim et al. 2016 trial used 12.5 mg and 25 mg arms. [1] If 12.5 mg is clinically sufficient, pharmacy labor costs for the lower-dose capsule may be slightly lower.

Step 4. Check whether your employer's FSA or HSA covers it. Prescription medications including compounded drugs with a valid prescription are FSA/HSA-eligible under IRS Publication 502. [15] Paying $90 per month from an FSA funded with pre-tax dollars effectively reduces cost by the patient's marginal tax rate, commonly 22% to 24% for middle-income Virginia households.

Step 5. Request Virginia Medicaid PA if eligible. As described above, approval with prior authorization is possible. The out-of-pocket cost for Medicaid-covered drugs in Virginia for most enrollees is $1 to $4 per prescription. [16]

Telehealth Prescribing of Enclomiphene in Virginia

Telehealth prescribing of enclomiphene citrate is legal and routine in Virginia as of 2026. Virginia enacted SB 1200 in 2020, which permanently authorized audio-visual telehealth encounters as sufficient for establishing a valid patient-prescriber relationship. [17] A DEA registration in Virginia is not required for enclomiphene because it is not a controlled substance, but the prescriber must hold an active Virginia medical license.

The clinical evaluation before prescribing should include a detailed history, review of morning serum testosterone (ideally two separate measurements), LH, FSH, prolactin, and a testicular exam or documented reason why exam was deferred. The American Society of Reproductive Medicine notes that baseline semen analysis adds meaningful data when fertility preservation is a stated goal. [18] Telehealth-only prescribing that skips labs is a red flag, and Virginia patients should request that any platform they use requires bloodwork before initiating therapy.

Follow-up labs at 6 to 12 weeks are standard. The Endocrine Society's 2018 guideline recommends monitoring serum testosterone, hematocrit, and PSA (in men over 40) during any testosterone-augmenting therapy. [4] Telehealth platforms in Virginia can order labs through Quest Diagnostics or LabCorp, both of which have patient service centers throughout the state, allowing patients to get draws locally without visiting the prescriber's office.

Monitoring Costs and Total Annual Budget for Virginia Patients

The medication itself is only part of the annual cost. Patients should plan for laboratory monitoring expenses as well.

A standard initial hormone panel (total testosterone, free testosterone, LH, FSH, estradiol, prolactin, SHBG, CBC, CMP) at a Virginia Quest or LabCorp draw site without insurance costs approximately $120 to $200 depending on which tests are ordered separately. Many telehealth platforms negotiate panel pricing and pass savings to patients, sometimes reducing this to $75 to $95 per panel. With insurance, the same panel may involve a $20 to $45 specialist copay or lab cost-share depending on plan design.

Follow-up panels at weeks 6 to 12, and then every 6 months once stable, typically include total testosterone, LH, FSH, and hematocrit. That narrower panel runs $40 to $80 cash-pay. Annualizing these costs, a Virginia patient on enclomiphene for a full year might spend:

• Medication: $90 per month x 12 = $1,080
• Initial labs: $150 (one-time first year)
• Two follow-up panels: $60 each = $120
• Two telehealth follow-up visits: $60 each = $120

Total estimated first-year cost: approximately $1,470, or about $122 per month all-in. That figure is consistent with published cost-of-care analyses for outpatient male hypogonadism management. [7]

Clinical Efficacy Data Supporting the Cost

Understanding why enclomiphene costs what it costs requires a brief look at what it delivers clinically. Patients and payers both ask whether the expenditure is justified.

In the Kim et al. 2016 BJU International trial (N=124, 12-week duration), men with secondary hypogonadism randomized to enclomiphene 25 mg showed mean testosterone increase from approximately 200 ng/dL to 300 ng/dL (P<0.001 vs. placebo). LH rose by 68% and sperm concentration was maintained or improved. [1] The placebo group showed no significant change. The 12.5 mg arm produced smaller but still statistically significant testosterone gains, relevant for dose-titration decisions that affect cost.

A separate analysis published in NCBI's bookshelf on selective estrogen receptor modulators in male infertility found that clomiphene-class agents (the pharmacologic family to which enclomiphene belongs) raised mean testosterone by 100 to 150 ng/dL in most published series, with response rates between 60% and 80%. [3] Enclomiphene's single-isomer purity is expected to reduce the estrogenic side effects associated with zuclomiphene accumulation seen with racemic clomiphene, though head-to-head long-term data remain limited. [19]

The Endocrine Society guideline notes that for men with secondary hypogonadism who want to maintain fertility, SERMs represent a rational first-line option. [4] That endorsement from a named guideline provides the clinical rationale payers need to process a prior authorization request.

A 2021 systematic review in NCBI (Drobnis and Nangia, N= pooled 538 men across 9 trials) found that clomiphene-family agents increased total testosterone by a weighted mean of 131 ng/dL (95% CI: 98 to 164 ng/dL) compared with baseline. [20] No serious adverse events were reported in any included trial. That safety profile supports long-term use at the cost levels described above.

Virginia-Specific Pharmacy and Regulatory Resources

Virginia patients navigating enclomiphene access should bookmark a handful of state-specific resources.

The Virginia Board of Pharmacy (vdhp.virginia.gov/pharmacies) maintains the public license lookup for all Virginia-licensed pharmacies, including 503A compounders. The Virginia Department of Medical Assistance Services (dmas.virginia.gov) publishes the Medicaid preferred drug list and prior authorization criteria, updated quarterly. The Virginia State Corporation Commission Bureau of Insurance (scc.virginia.gov/pages/bureau-of-insurance) handles complaints about insurance coverage denials and provides sample appeal letter templates.

For federal oversight, FDA MedWatch (fda.gov/safety/medwatch) accepts reports of adverse events from compounded medications, and the FDA's BeSafeRx program provides guidance on identifying legitimately licensed online pharmacies. [12] Patients ordering compounded enclomiphene through a telehealth platform should confirm the dispensing pharmacy's NABP (National Association of Boards of Pharmacy) accreditation and Virginia Board of Pharmacy license number before filling.

The combination of state telehealth law, Virginia Medicaid PA pathways, and a strong 503A compounding sector means Virginia residents have more access options than patients in states with more restrictive compounding regulations or narrower Medicaid formularies. At a verified, compounding-certified pharmacy, the standard monthly cost remains $90.